Calendario de inmunizaciones de la Asociación Española de Pediatría: recomendaciones 2023
- Francisco José Álvarez García
- María José Cilleruelo Ortega
- Javier Álvarez Aldeán
- María Garcés-Sánchez
- Elisa Garrote Llanos
- Antonio Iofrío de Arce
- Abián Montesdeoca Melián
- María Luisa Navarro Gómez
- Valentín Pineda Solas
- Irene Rivero Calle
- Jesús Ruiz-Contreras
- Pepe Serrano Marchuet
ISSN: 1695-4033, 1696-4608
Year of publication: 2023
Volume: 98
Issue: 1
Pages: 58-58
Type: Article
More publications in: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )
Abstract
As it does every year, the CAV-AEP publishes the update of its recommendations for the use of vaccines in children, adolescents and pregnant women residing in Spain. The 2 + 1 schedule is maintained in infants (at 2, 4 and 11 months), including preterm infants, with the hexavalent vaccine (DTaP-IPV-Hib-HB) and the pneumococcal 13-valent conjugate vaccine. A booster dose with DTaP-IPV is needed at 6 years for those who received the 2 + 1 series with hexavalent vaccine as infants, in addition to 1 dose of dTap in adolescence. Routine vaccination of pregnant women with a dose of dTap is recommended in each pregnancy, preferably between weeks 27 and 32 of gestation, although can be given from 20 weeks if there is risk of preterm delivery. All infants should receive the rotavirus vaccine (2–3 doses) and the 4 CMenB vaccine (2 + 1 series). All children aged 6–59 months should be vaccinated against influenza each year, in addition to risk groups from 6 months. The MenACWY vaccine should be given routinely at 12 months of age and in adolescence between ages 12 and 18 years. The recommendations for the MMR vaccine (12 months and 3–4 years) and varicella vaccine (15 months and 3–4 years) also remain unchanged, using the MMRV vaccine for the second dose. Recommendations for the use of SARS-CoV-2 vaccines in the paediatric age group will be updated periodically on the CAV-AEP website. The HPV vaccine is indicated in all adolescents, regardless of sex, at age 12 years. Novelties include the recommendation of routine administration of nirsevimab to neonates and infants aged less than 6 months for passive immunization against RSV, and the recommendations regarding the hexavalent vaccine are consolidated in a single section.